BERLIN -- Administering bone-modifying agents (BMAs) every 24 weeks after long-term use was a safe and effective strategy for ...

Inhibrx Biosciences’ antibody ozekibart has notched a key phase 2 win in a rare bone cancer that currently has no approved ...

Kids with a rare bone cancer called Ewing sarcoma might live longer if prescribed pazopanib, a drug that blocks blood supply ...

Ewing sarcoma is one of the most common bone cancers seen in children, and if it spreads, it can be deadly. One study found ...

Inhibrx Biosciences said on Thursday its experimental drug helped slow the progression of a rare and aggressive bone cancer in a mid-stage trial, sending its shares surging over 70% in extended ...

The position statement from cancer and bone societies updates recommendations from 2017 for managing bone loss and fracture ...

Bone cancer represents a serious medical condition that affects thousands of people each year, yet many individuals remain unfamiliar with its characteristics, symptoms, and treatment approaches.

Men with recurrent prostate cancer following surgery or radiation therapy may now have a new chance to live longer. A massive ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...